BLMH
BLMH (bleomycin hydrolase, also known as BH or BMH) is a cytoplasmic cysteine peptidase of the papain superfamily. It is best known for inactivating the glycopeptide anticancer drug bleomycin, although its normal physiological role is unknown. Browse Assay Genie's current range of BLMH research reagents below, or read on for the biology behind the target.
BLMH catalyses the inactivation of bleomycin (BLM), a glycopeptide antitumour drug, by hydrolysing the carboxamide bond of its B-aminoalaninamide moiety. In doing so it protects both normal and malignant cells from bleomycin toxicity. Bleomycin is an essential component of combination chemotherapy regimens for cancer, which is why this enzyme is of interest in studies of drug response and resistance. Beyond this activity, the normal physiological role of BLMH is unknown, and the metabolic inactivation of bleomycin is the only known activity of the enzyme.
BLMH is a cytoplasmic cysteine peptidase and is also found in cytoplasmic granules. It belongs to the peptidase C1 family, within the HGNC gene groups for peptidase family C1 and cysteine endopeptidases. The protein contains the signature active site residues of the papain superfamily of cysteine proteases, and it is highly conserved through evolution. Orthologues of the human BLMH gene are annotated in mouse (Blmh) and rat (Blmh).
The enzyme is listed under EC 3.4.22.40 and is also referred to as BH or BMH in the literature. Because its endogenous function remains undefined, BLMH is studied both as a bleomycin-metabolising enzyme and as a conserved member of the papain-like peptidase family. Researchers working with the BLMH protein, the BLMH gene or BLMH antibody and ELISA-based detection approaches typically do so in the context of bleomycin metabolism and cysteine protease biology.
BLMH inactivates bleomycin, a component of combination chemotherapy, so it is studied in relation to protection of normal and malignant cells from drug toxicity.
The only known activity of BLMH is the metabolic inactivation of bleomycin by hydrolysis of its B-aminoalaninamide carboxamide bond.
BLMH carries the signature active site residues of the papain superfamily and belongs to peptidase family C1, making it a model for papain-like enzymes.
The enzyme is highly conserved through evolution, yet its normal physiological role is unknown, which keeps its function an open research question.
BLMH is a cytoplasmic cysteine peptidase that inactivates the antitumour glycopeptide bleomycin by hydrolysing the carboxamide bond of its B-aminoalaninamide moiety. This protects normal and malignant cells from bleomycin toxicity. Its normal physiological role is unknown.
BLMH stands for bleomycin hydrolase, and the protein is also called BH or BMH. The enzyme is classified as EC 3.4.22.40 and sits in the peptidase C1 family, within the HGNC groups for peptidase family C1 and cysteine endopeptidases.
Yes. BLMH is described as highly conserved through evolution, and orthologues are annotated in mouse and rat, both named Blmh. Check the datasheet of any product for its validated reactivity.
Other peptidase C1 family cysteine peptidases and papain-like enzymes with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q13867; product specifications from Assay Genie datasheets.